Navigation Links
Photons vs. protons for treatment of spinal cord gliomas
Date:12/22/2010

COLUMBUS, Ohio A study comparing the long-term outcomes of patients with spinal-cord tumors following radiation therapy suggests that certain subsets of patients have better long-term survival. It also suggests that photon-based radiation therapy may result in better survival than proton-beam therapy, even in patients with more favorable characteristics.

This is the first study to report the long-term outcomes of spinal-cord tumor patients treated by modern radiotherapy techniques, the researchers say. Gliomas, which represent most spinal cord tumors, develop in about 17,000 Americans annually, and 13,000 die from them.

"Our findings need to be verified in a larger number of patients, but they suggest that individuals younger than age 54, those with ependymomas and those treated with photon-based therapy versus proton-beam treatment have better overall survival," says principal investigator Dr. Arnab Chakravarti, chair and professor of Radiation Oncology and co-director of the Brain Tumor Program at The Ohio State Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

"Perhaps most surprising is that the subset of spinal-cord tumor patients treated by protons appears to do worse, even though they have more favorable pretreatment demographics," Chakravarti says. "This certainly warrants validation in a larger subset of patients."

Surgery is the standard therapy for spinal-cord tumors, and it is often followed by radiotherapy. But whether all patients or only certain patients should receive radiation therapy is controversial, Chakravarti says.

The research is published in a recent issue of the International Journal of Radiation Oncology, Biology, Physics.

The retrospective study examined the long-term outcomes of 32 patients with primary spinal-cord gliomas. Twenty-two of the patients were treated with photon-beam radiation therapy (such as 3-D conformal radiation and intensity-modulated radiotherapy), and 10 were treated with proton-beam therapy.

The five-year overall survival rate was 65 percent and the progression free survival was 61 percent for the group. The study also showed poorer overall survival for the following patients:

  • Those age 55 and older.
  • Those with astrocytomas versus ependymomas.
  • Those who had a biopsy versus those whose tumor was surgically removed.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Age plays too big a role in prostate cancer treatment decisions
2. UH biochemist works to revolutionize ovarian cancer treatment
3. Factors linked to speech/swallowing problems after treatment for head and neck cancers
4. Training the best treatment for tennis elbow
5. FDA Advises Against Avastin as Treatment for Breast Cancer
6. New combo lung cancer therapy improves survival over single-line treatment
7. Gene information predicts survival time, possible new treatment options for lung-cancer patients
8. Protein offers new clue to cause and treatment for kidney disease
9. Depression drug may relieve pain from breast cancer treatment, U-M study finds
10. Bone Drug Zometa Flops Overall as Breast Cancer Treatment
11. Official food allergy treatment guidelines released
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... enrichment program serving the greater Venice, FL area, has initiated a fundraiser for ... a car accident just four days after Christmas. To support this beautiful child ...
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying ... , According to Perry A~, author of “Calcium Bentonite Clay” the health benefits of ... in balancing and detoxifying the body. , A former motivational speaker, Perry A~ has ...
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show where ... see the most incredible gardens and home improvement experts that attend this amazing show. ... - 700 14th St. Denver CO, is an exciting event that Performance Mobility has ...
(Date:2/8/2016)... KS (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com ... leader in Mole removal products. , Moles are derived from a cluster of melanin ... in all the wrong places and create a lifetime of embarrassment. Historically, mole ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare ... helpful interventions and causes of chronic illness in children. , Very recent articles have ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016 Velano Vascular, a medical ... hospitalized patients and their practitioners, announced today that the ... Velano will use the proceeds from this financing, an ... in January 2015, to support the development and commercialization ... pediatric populations. Philadelphia , ...
(Date:2/8/2016)... CARLSBAD, Calif. , Feb. 8, 2016  HemaFlo Therapeutics, ... Office (USPTO) has issued US Patent Number 9,119,880 covering the ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ... technology." --> Dale Peterson , PhD, HemaFlo,s ... such a powerful technology." --> Dale ...
(Date:2/8/2016)... , Feb. 8, 2016  Astellas Pharma Inc. President and ... promotion of James Robinson as president, Americas Operations, ... in North and South America , effective ... US, representing the commercial organization in the United ... Masao Yoshida , who is retiring in ...
Breaking Medicine Technology: